Cytek Biosciences, Inc. (NASDAQ:CTKB) Q1 2024 Earnings Call Transcript

Page 3 of 3

Wenbin Jiang: The facility is to support across the board for our product manufacturing, mostly instrument manufacturing.

Jacqueline Kisa: Great. And if I could just sneak one more in. Late last year, you launched a software improvement on Northern Lights. Have you received any feedback from that from customers? And is there any room for similar product improvements on the rest of the portfolio?

Wenbin Jiang: Well, actually, we do have heard encouraging comment from the customer with regarding to the new software, which enables those conventional instrumentations to manage the special features. In the meantime, reduce the kind of barriers to move from one platform to the other that I think we feel it’s a great success.

Operator: [Operator Instructions] There are no further questions at this time. Ladies and gentlemen, that concludes today’s call. Thank you all for joining. You may now disconnect.

Follow Cytek Biosciences Inc.

Page 3 of 3